Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases.
about
Recent advancements in erythrocytes, platelets, and albumin as delivery systemsOvercoming drug efflux-based multidrug resistance in cancer with nanotechnologyChemotherapy-enhanced inflammation may lead to the failure of therapy and metastasisThe Role of TLR4 in Chemotherapy-Driven MetastasisA Platform for Rapid, Quantitative Assessment of Multiple Drug Combinations Simultaneously in Solid Tumors In VivoWeekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinomaSmall-sized polymeric micelles incorporating docetaxel suppress distant metastases in the clinically-relevant 4T1 mouse breast cancer modelLymphatic endothelial progenitors originate from plastic myeloid cells activated by toll-like receptor-4The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer.Interpatient pharmacokinetic and pharmacodynamic variability of carrier-mediated anticancer agents.Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner.Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer.The interconnectedness of cancer cell signaling.The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents.The mesenchymal tumor microenvironment: a drug-resistant niche.Novel model for basaloid triple-negative breast cancer: behavior in vivo and response to therapy.TLR4 is a novel determinant of the response to paclitaxel in breast cancerSWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.Cancer subclonal genetic architecture as a key to personalized medicine.Tranilast-induced stress alleviation in solid tumors improves the efficacy of chemo- and nanotherapeutics in a size-independent manner.Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents.JD enhances the anti-tumour effects of low-dose paclitaxel on gastric cancer MKN45 cells both in vitro and in vivo.The effect of paclitaxel and nab-paclitaxel in combination with anti-angiogenic therapy in breast cancer cell lines.Novel role of immature myeloid cells in formation of new lymphatic vessels associated with inflammation and tumors.Sonic-hedgehog pathway inhibition normalizes desmoplastic tumor microenvironment to improve chemo- and nanotherapy.Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integrationMechanistic modeling quantifies the influence of tumor growth kinetics on the response to anti-angiogenic treatment.Evaluation of Anti-Metastatic Potential of the Combination of Fisetin with Paclitaxel on A549 Non-Small Cell Lung Cancer Cells.Nanoparticle-Mediated Therapeutic Agent Delivery for Treating Metastatic Breast Cancer-Challenges and Opportunities.mouse study identifies tumour growth kinetics as biomarkers for the outcome of anti-angiogenic treatment
P2860
Q26747764-35D3808B-2783-4885-AB34-88C04CAAD1AFQ26849264-D0BE1457-D323-41CF-AF9F-85F7F1675253Q26858839-B29983B9-C4D2-40BB-B73C-68FBEE88CC0BQ26861495-78837902-FEEA-4EE8-903C-832348B05D30Q28552262-6560AB21-1AD2-49D3-B6E7-66345841B04BQ33435812-6999C041-0F65-4B8C-89BD-C6D100866648Q33622043-7606A63B-DF98-4C13-87D8-DA8463F3F974Q33783644-99C02958-CFA5-4320-B4D2-968550D6A5FBQ34086875-0BC578FE-F2C1-4A4A-A2D7-B19AFF6EF813Q34265621-F47119A3-1636-45E1-948B-CCAC7FCBC0DDQ34290191-100E0735-640E-44F7-BA92-D44DEA9832E9Q34608899-E182F70A-DB4B-4026-B8E2-E4135D67D649Q35669733-C204F336-CD9B-4E96-8D65-BE98DAA713EFQ36126057-29394CCA-CBC6-4736-B65D-74BCAE7A964BQ36187755-E19BFA70-9994-4A9A-BCC2-C0F46292774AQ36343773-61F1F7B5-F258-4938-AA42-A970E5C42529Q37093119-40F2FD67-93AA-4D95-869D-BFA714499028Q37131869-A5AD324E-F3E8-47FF-8CC0-41C4B134EA7AQ37448116-3EF0C41B-537E-47B3-99CD-367CFF39D4DCQ37743995-E87D0FD4-0F03-4C3F-A5BE-24F43358469BQ38546964-6FBDD3DA-3A1A-423C-8964-E9EC4275F871Q38736541-C043440C-6015-467E-B339-1E964BFF592CQ38878437-5D755973-3246-45A1-ADEB-EFD6ABFCE536Q39241349-70B1D9D1-4AD1-4664-B947-6BBA875C56D4Q41301719-F54ED42F-7F54-45FC-B009-1136FC43977DQ41879186-63A2C9BB-305C-4506-8A34-827531F26D68Q47228068-6A03E930-F850-4182-B380-170F51F5CB0AQ52679106-1DFAE30A-0D0F-4218-A761-03887088BCA9Q55633505-11F8B017-36F7-4888-8592-45E1F46591B2Q58718463-B21A4F6E-2BD6-45BE-8CA2-A274D453F2CF
P2860
Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Synergy of nab-paclitaxel and ...... rs and preexisting metastases.
@ast
Synergy of nab-paclitaxel and ...... rs and preexisting metastases.
@en
Synergy of nab-paclitaxel and ...... rs and preexisting metastases.
@nl
type
label
Synergy of nab-paclitaxel and ...... rs and preexisting metastases.
@ast
Synergy of nab-paclitaxel and ...... rs and preexisting metastases.
@en
Synergy of nab-paclitaxel and ...... rs and preexisting metastases.
@nl
prefLabel
Synergy of nab-paclitaxel and ...... rs and preexisting metastases.
@ast
Synergy of nab-paclitaxel and ...... rs and preexisting metastases.
@en
Synergy of nab-paclitaxel and ...... rs and preexisting metastases.
@nl
P2093
P2860
P356
P1433
P1476
Synergy of nab-paclitaxel and ...... rs and preexisting metastases.
@en
P2093
Deena Chihade
Lisa D Volk
Michael J Flister
Neil Desai
Sophia Ran
Vuong Trieu
P2860
P304
P356
10.1593/NEO.101490
P577
2011-04-01T00:00:00Z